oncodaily - Purdue Institute for Cancer Research shared a post on LinkedIn: “Purdue researchers, including Nicolás Morato and R. Graham Cooks, have developed a next-generation platform that integrates chemical synthesis, biological testing, […]
AI Summary: Purdue researchers unveiled an automated mass‑spectrometry platform that compresses key steps of small‑molecule drug discovery into a matter of hours, promising faster lead identification and screening. The system couples high‑throughput chemistry with rapid readouts to accelerate iteration cycles, potentially shrinking timelines and costs for early oncology drug development — welcome news for impatient scientists.
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 4 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days
Phages repurpose vaccine immunity to attack cancer cells / 12 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days
Some tumors kill neighboring healthy cells to fuel growth / 4 wks
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 5 wks
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 5 wks
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.